La chaîne d'options affiche les données clés des options sur actions de Kairos Pharma à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Kairos Pharma..

Kairos Pharma (AMEX:KAPA) Stock, Chaîne d'Options

KAIROS PHARMA LTD

Kairos Pharma

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Community Financial System, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBU#NYSE">CBU</a>) (the "Company") announced that it has declared a quarterly cash dividend of $0.47 per share on its common stock. The dividend will be payable on October 10, 2025 to shareholders of record as of September 12, 2025.
The $0.47 cash dividend represents a $0.01, or 2.2%, increase and an annualized yield of 3.33% based on the closing share price of $56.40 on July 15, 2025. President and Chief Executive Officer, Dimitar Karaivanov, commented, "Today's increase reflects the Board of Directors' confidence in our sustainable long-term growth strategy as a diversified financial services company. Our annual dividend increases over the last 33 years are supported by our strong balance sheet and cash flow generation that provide us with flexibility to return cash to our Shareholders while investing in our long-term future."

News

Dividends

Community Financial System Raises Quarterly Cash Dividend From $0.46 To $0.47 Per Share

Buybacks

BPOP

Popular Increases Its Quarterly Common Stock Dividend From $0.70 To $0.75 Per Share; Announces New Stock Repurchase Program Of Up To $500M

Greif Announces Virtual Power Purchase Agreement; To Purchase ~100 GWh Per Year Of Clean, Renewable Energy

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 33.33% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 21.60% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 19.35% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 13.79% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 12.40% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 11.11% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 10.17% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 9.66% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 7.14% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 5.71% at $8.52</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 5.14% at $3.30</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 30.84% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 24.29% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 20.00% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 16.67% at $0.0005</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 16.13% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 12.71% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed down 9.52% at $0.40</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 8.11% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 6.85% at $0.31</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 5.15% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 4.74% at $0.92</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 4.52% at $0.03</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BBRRF

BLGVF

CBDY

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNBX

CNTMF

CRBP

CVSI

CXXIF

FFNTF

GBHPF

GNLN

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

LVRLF

MRMD

RMHB

SOLCF

TGIFF

UGRO

YCBD

Cannabis Stock Gainers And Losers From July 16, 2025

Contracts

Granite Construction Wins $17M Contract By Utah Department Of Transportation For Bridge Replacement Project In Riverdale, Utah

Regions Financial  Increases Dividend From $0.25 To $0.265/Share

WIIM

MP Materials shares are trading lower after the company announced a $500 million proposed public offering.

The J.M. Smucker Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) today announced its Board of Directors approved an increase in the quarterly dividend from $1.08 to $1.10 per common share, an increase of two percent. The next dividend will be paid on Tuesday, September 2, 2025, to shareholders of record at the close of business on Friday, August 15, 2025. The Company remains committed to returning value to shareholders, as this represents the 24th consecutive fiscal year of dividend growth.

J.M. Smucker Increases Quarterly Dividend By 2% From $1.08 To $1.10 Per Share

Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) has outperformed the market over the past 5 years by 2.05% on an annualized basis producing an average annual return of 16.0%. Currently, Analog Devices has a market capitalization of $119.42 billion. 
Buying $1000 In ADI: If an investor had bought $1000 of ADI stock 5 years ago, it would be worth $2,055.44 today based on a price of $240.64 for ADI at the time of writing.
<h3>Analog Devices's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752697811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Offerings

MP Materials Reveals Commencement of Proposed $500M Public Offering of Common Stock

FLYY

Spirit Aviation Holdings To Offer 6,283,197 Shares By Selling Stockholders

On July 15, 2025, LQR House Inc., a Nevada corporation (the "Company"), became aware that the Company and its entire board of directors have been named as defendants, along with over one dozen other defendants, which alleges, among other things, breach of fiduciary duties, violations of the Nevada Revised Statutes 78.650, 78.630, 207.400 90.570 and 32.010, alter ego liability, civil conspiracy (the "Complaint"). The Complaint seeks, among other things, a declaratory judgment, a temporary restraining order and preliminary injunction freezing the Company's assets, the assets of the Company's Chief Executive Officer, Sean Dollinger, the assets of any of the other defendants controlled by Sean Dollinger and others, injunctive relief to prevent any further material corporate decisions by the Company, the court restrain the Company, its directors, officers and stockholders from making any significant changes to the Company's governance or capital structures to further entrench the Company's Chief Executive Officer a receiver be appointed over the Company and undisclosed monetary damages. The Complaint was filed by Kingbird Ventures, LLC, on July 11, 2025, before the Eighth Judicial District Court in Clark County, Nevada. The Company has not yet been served with the Complaint or any other papers related thereto. The Company has no indication in its books and records of Kingbird Ventures LLC and has no information as to its identity or that it is even a shareholder. The Company intends on vigorously defending the litigation as, on its face, there are a myriad of facts upon which the plaintiff relies that are inherently false. However, no assurances can be made as to any outcome of this litigation.
&nbsp;

Legal

LQR House And Entire Board Named In Lawsuit Alleging Breach Of Fiduciary Duty And Seeking Asset Freeze, Injunctions, And Receivership; Company Denies Allegations And Vows To Defend Vigorously

Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) released its second-quarter results after Wednesday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/07/b46454434/kinder-morgan-reports-second-quarter-2025-financial-results">from the quarter. </a>
The Details: Kinder Morgan reported quarterly earnings of 28 cents per share, which beat the analyst consensus estimate of 27 cents, according to<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"> Benzinga Pro</a>.
Quarterly revenue came in at $4.04 billion, which beat the analyst consensus estimate of $3.74 billion and is an over revenue of $3.572 billion from the same period last year.
Read Next:<a href="https://www.benzinga.com/markets/tech/25/06/45971345/sunrun-first-solar-plunge-solar-stocks-hit-hard-by-trump-tax-bill-latest?utm_source=articleShare"> </a><a href="https://www.benzinga.com/markets/tech/25/07/46422009/rare-earth-royalty-meet-the-power-players-shaping-the-industry?utm_source=articleShare">Rare Earth Royalty: Meet The Power Players Shaping The Industry</a>
&#8220;With historic growing natural gas demand forecasts, a positive federal regulatory environment, and highly supportive federal permitting agencies, the future for our company is very bright. We will continue to reap the benefit of a business model structured around long-term take-or-pay, fee-based contracts with credit-worthy customers,&#8221; said Executive Chairman Richard D. Kinder.
Outlook:&nbsp;Kinder Morgan affirmed its fiscal 2025 adjusted EPS guidance of $1.27 per share, versus the $1.27 estimate. 
KMI Price Action: According to data from<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"> Benzinga Pro</a>, Kinder Morgan stock was up 0.14% at $27.95 in Wednesday's extended trading. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46374434/joby-aviation-stock-goes-vertical-as-secret-massive-drone-achieves-9-hour-flight?utm_source=articleShare">Joby Aviation Stock Goes Vertical As Secret, Massive Drone Achieves 9-Hour Flight</a></li>
</ul>
Photo: Shutterstock

Earnings

Commodities

After-Hours Center

Kinder Morgan Reports Better-Than-Expected Q2 Results: Details

Transocean Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) today issued a quarterly Fleet Status Report that provides the current status of, and contract information for, the company's fleet of offshore drilling rigs.
This quarter's report includes the following updates:
<ul>
<li>Transocean Equinox – Customer exercised two one-well options in Australia at a dayrate of $540,000.</li>
<li>Transocean Spitsbergen – Customer exercised a two-well option in Norway at a dayrate of $395,000.</li>
<li>Deepwater Skyros – Awarded a three-well contract in Ivory Coast, plus a one-well option at a dayrate of $361,000.</li>
<li>Deepwater Mykonos – Awarded a 60-day extension in Brazil, plus options up to an incremental 120 days. &nbsp;</li>
</ul>
The aggregate incremental backlog associated with these fixtures is approximately $199 million. As of July 16, 2025, the company's total backlog is approximately $7.2 billion.&nbsp;&nbsp;

Transocean Adds $199M To Backlog With New Rig Contracts In Australia, Norway, Ivory Coast, And Brazil; Total Backlog Reaches ~$7.2B

BRCC

BRC shares are trading lower after the company announced a proposed public offering.

SL Green Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) raises FY2025 FFO guidance from $5.25-$5.55 to $5.65-$5.95 vs $5.46 analyst estimate..

Guidance

SL Green Realty Raises FY2025 FFO Guidance from $5.25-$5.55 to $5.65-$5.95 vs $5.46 Est

BLMZ

BloomZ shares are trading higher after the company announced it will invest and form a strategic partnership with Myth Korea.

Triumph Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFIN#NASDAQ">TFIN</a>) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.08 by 97.37 percent. This is a 87.5 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $108.06 million which beat the analyst consensus estimate of $105.83 million by 2.11 percent. This is a 2.84 percent increase over sales of $105.08 million the same period last year.

Earnings Beats

TFIN

Triumph Financial Q2 EPS $0.15 Beats $0.08 Estimate, Sales $108.06M Beat $105.83M Estimate

The U.S. Department of Energy announced a pivotal new program to resurrect America&#8217;s nuclear fuel supply chain, a development that potentially places domestic uranium producer Energy Fuels Inc (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UUUU#AMEX">UUUU</a>) in a favorable position.
What To Know: The DOE on Wednesday <a href="https://www.energy.gov/articles/energy-department-announces-pilot-program-build-advanced-us-nuclear-fuel-lines-and-end">issued</a> a Request for Application inviting qualified U.S. companies to build and operate nuclear fuel production lines. This initiative aims to eliminate U.S. reliance on foreign enriched uranium and fuel the nation&#8217;s advanced reactor development.
Energy Fuels, which owns and operates the White Mesa Mill in Utah, the only fully licensed conventional uranium mill in the U.S., is seen as a primary candidate. The company&#8217;s <a href="https://www.benzinga.com/pressreleases/25/06/n46106647/energy-fuels-donald-rare-earth-and-mineral-sand-joint-venture-in-australia-receives-final-major-re">existing infrastructure</a>, operational expertise and stated ambition to create an integrated domestic fuel cycle align directly with the program&#8217;s objectives and criteria of technological readiness.
The initiative provides a fast-tracked DOE authorization process intended to de-risk and attract private investment into fuel fabrication. While selected companies will bear all costs, participation could secure long-term strategic value. 
For Energy Fuels investors, this government-backed push to onshore the nuclear supply chain represents a significant potential catalyst, validating the company&#8217;s strategic importance in America&#8217;s &#8220;<a href="https://www.energy.gov/articles/energy-department-announces-pilot-program-build-advanced-us-nuclear-fuel-lines-and-end">nuclear renaissance</a>.&#8221; Initial applications are due Aug. 15, 2025.
Benzinga Edge Rankings: According to <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> stock rankings, Energy Fuels exhibits exceptionally strong price momentum with a score of 87.68. This high rating indicates the stock has been outperforming its peers significantly in recent price action. 
However, the stock scores poorly on fundamental metrics. Its Value score is a low 25.19, suggesting it may be expensive relative to its financial performance. Similarly, its Growth score is weak at 23.73, pointing to lackluster historical or projected growth. 
This data profile characterizes UUUU as a stock with strong recent trading performance but weaker underlying value and growth fundamentals.
UUUU Price Action: According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Energy Fuel shares closed Wednesday&#8217;s session higher by 6.19% to $8.24. The stock has a 52-week high of $8.29 and a 52-week low of $3.20.
<h2 class="wp-block-heading">How To Buy UUUU Stock</h2>
By now, you're likely curious about how to participate in the market for Energy Fuels — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Energy Fuels, which is trading at $8.24 as of publishing time, $100 would buy you 12.14 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option or sell a call option at a strike price above where shares are currently trading; either way, it allows you to profit from the share price decline.
Read Also: • <a href="https://www.benzinga.com/pressreleases/25/07/n46189952/energy-fuels-pinyon-plain-uranium-mine-continues-to-outperform">Energy Fuels&#8217; Pinyon Plain Uranium Mine Continues To Outperform</a>
Image: Shutterstock

Government

UUUU

Energy Fuels Stock Soars As DOE Launches Domestic Nuclear Fuel Initiative

<a href="https://truthsocial.com/@realDonaldTrump/114864763487869986" title="https://truthsocial.com/@realDonaldTrump/114864763487869986">https://truthsocial.com/@realDonaldTrump/114864763487869986</a>

President Trump Posts On Truth Social "I have been speaking to Coca-Cola about using REAL Cane Sugar in Coke in the United States, and they have agreed to do so. I'd like to thank all of those in authority at Coca-Cola. This will be a very good move by them — You'll see. It's just better!"

Press Releases

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Kairos Pharma Ltd. Provides Letter to Stockholders

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Tech Momentum Surges as IPA, HIT, SNYR, PNPN.V, KAPA and Others Drive Investor Awareness – More Stocks Inside

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Comments

Kairos Pharma

Kairos Pharma (KAPA) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL